secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274069
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica posts Q3 2023 net loss of $24.8M; first YCANTH revenue $2.8M
--------------------------------------------------------------------

- First commercial YCANTH sale to distributor FFF generated $2.8M product revenue; net loss $24.8M ($0.54/share).
- Non-GAAP net loss $14.8M ($0.32/share) vs. non-GAAP net income $2.9M in Q3 2022.
- SG&A surged to $20.1M (from $3.9M) due to YCANTH commercial ramp and $7.4M stock compensation.
- Over 112M lives covered by commercial/managed Medicaid; fee-for-service Medicaid in 4 states.
- Cash $84.3M; closed $125M OrbiMed debt facility ($50M drawn) to fund operations into Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/0001193125-23-274069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/d280768d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer